To Evaluate the Mass Balance Recovery, Metabolite Profile and Metabolite Identification in Healthy Male Subjects
Launched by JW PHARMACEUTICAL · Jun 16, 2025
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a new medicine is processed and broken down in the bodies of healthy adult men. The researchers want to understand where the medicine goes in the body, how much of it is recovered after being taken, and what new substances (called metabolites) it turns into. This helps scientists learn more about how the medicine works and how safe it might be.
To take part in this study, you need to be a healthy adult male. The trial is currently not recruiting participants yet, but when it starts, volunteers can expect to be closely monitored as they take the medicine. This usually involves giving the medicine and then having tests done to track how it moves through the body over time. If you are healthy and meet the criteria, you might be eligible to join once the study begins.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Healthy volunteers
- Exclusion Criteria:
- • 1. Subjects does not meet the Inclusion Criteria
About Jw Pharmaceutical
JW Pharmaceutical is a leading South Korean biopharmaceutical company dedicated to advancing healthcare through innovative research and development of novel therapeutics. With a strong focus on oncology, neurology, and rare diseases, JW Pharmaceutical leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company is committed to conducting high-quality clinical trials that adhere to rigorous ethical standards, ensuring patient safety and efficacy of its products. Through strategic partnerships and collaborations, JW Pharmaceutical aims to deliver impactful therapies that enhance the quality of life for patients globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
McKenzie Litza, Principal Investigator
Principal Investigator
Quotient Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported